According to a report by Datamonitor published on 23 February 2011 the global biosimilars market will grow from US$243 million in 2010 to US$3.7 billion in 2015.
Global biosimilar market to grow to US$3.7 billion in 2015
Biosimilars/General
|
Posted 08/04/2011
0
Post your comment
In 2009, the combined biosimilars market size for the US and five major European markets was a mere US$150 million. The positive forecast by Datamonitor for 2015 is mainly based on the fact that between 2011 and 2015 more than 30 branded biologicals with sales of US$51 billion will lose their patent exclusivity.
The market analyst company believes that ‘due to their complexity, cost, and development risks’ biosimilar production will be limited to ‘only a handful of pharma companies, all of which are established generics players’. Although electronics giant, Samsung, has perhaps not listened to this advice—with their biosimilars deal with Quintiles announced on 28 February 2011.
Drivers for growth in the biosimilars market include the growing use of biologicals, and the need for more cost-effective treatments. However, there remain a large number of barriers, not least of which is the lack of guidance for the implementation of the biosimilars pathway in the US.
Related articles
Samsung to enter biosimilars market
US biosimilars pathway unlikely to be used
Source: Datamonitor
Research
Biosimilars in low- and middle-income countries
Positive safety and efficacy primary endpoint results for AVT05 (golimumab proposed biosimilar)
Related content
The ustekinumab shift: biosimilars displace Stelara’s market leadership
Biosimilars/General Posted 12/03/2025
Brazilian law establishes December 16 as National Biosimilar Day
Biosimilars/General Posted 05/03/2025
Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia
Biosimilars/General Posted 20/11/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment